News
🇺🇸 AmericasLatest pharmaceutical news, drug approvals, and FDA regulatory updates.
Breaking Arvinas VEPPANU (Vepdegestrant) Receives FDA Approval as First PROTAC Drug for ESR1-Mutated Breast Cancer
Arvinas' VEPPANU becomes the first FDA-approved PROTAC drug for ESR1-mutated, ER+/HER2- advanced breast cancer, marking a breakthrough in protein degradation therapy.
Latest News
Novo Nordisk Reports Record Q1 Revenue Driven by Wegovy and Ozempic Demand
Novo Nordisk has reported record Q1 revenue driven by strong demand for Wegovy and Ozempic. This article analyzes the implications for investors and the competitive landscape.
US-Japan Healthcare Conference: Day 1 Key Takeaways
The 2026 U.S.-Japan Healthcare Conference represents an important bilateral healthcare forum, but detailed Day 1 proceedings have not yet been released through official channels. NovaPharmaNews will provide verified coverage once official conference materials become available.
ISPOR 2026: Cardiology Advances in Cost-Effectiveness Research
ISPOR 2026 highlighted emerging cost-effectiveness frameworks for cardiovascular interventions and emphasized the critical role of real-world evidence in supporting value-based cardiology care and reimbursement decisions.
ASGCT 2024: Day 1 Key Takeaways in Gene Therapy Advancements
ASGCT 2024 Day 1 coverage: This article addresses data gaps in available materials while highlighting what readers should expect from gene and cell therapy presentations, regulatory updates, and manufacturing innovations discussed at the conference.
OCT East Coast: Key Takeaways from Day 1
OCT East Coast Day 1 proceedings require official conference materials and press releases for accurate reporting of speakers, presentations, and clinical data. NovaPharmaNews awaits verified information from OCT organizers.
BioMed Israel 2026: Key US Biotech Trends - Day 1 Roundup
BioMed Israel 2026 convened biotech stakeholders on Day 1, though comprehensive coverage of specific company presentations and announcements remains pending official conference materials and press releases.
BioNJ BioPartnering Conference: Biotech Innovation on Display
The BioNJ BioPartnering Conference convened biotech innovators, pharmaceutical executives, and investors to showcase emerging therapeutic platforms and forge strategic collaborations. The event highlighted trends in cell and gene therapy partnerships, rare disease focus, and early-stage venture investment.
BioMed Israel 2026: Key Takeaways for US Biotech Investors
BioMed Israel 2026 convened US and Israeli biotech stakeholders to explore partnership opportunities, showcasing innovations in diagnostics, drug delivery, and digital health while reinforcing the strategic importance of Israeli biotech within the US pharmaceutical investment landscape.
ASGCT 2026: Gene Therapy Manufacturing Innovations Emerge
ASGCT 2026 brought together gene therapy manufacturing experts to address scalability, regulatory compliance, and emerging technologies. Industry leaders emphasized the need for process optimization, automation, and AI-driven analytics to reduce costs and improve production efficiency.
US-Japan Healthcare Conf. Day 1: Key Takeaways
The 2026 U.S.-Japan Healthcare Conference Day 1 focused on regulatory harmonization, digital health innovation, and policy alignment to strengthen bilateral pharmaceutical and healthcare collaboration. Key discussions addressed market access barriers, aging population health challenges, and emerging opportunities in personalized medicine.
BioNJ BioPartnering Conference: Day 1 Highlights
The BioNJ BioPartnering Conference convened New Jersey's biotech community on Day 1 to explore partnership opportunities, emerging technologies, and strategic collaborations. Sessions focused on partnership models, early-stage funding, regulatory pathways, and trends including AI-driven drug discovery and capital efficiency.
BioMed Israel: Day 1 Highlights in Biotech Innovation
BioMed Israel 2026 is anticipated to continue its role as a premier platform for biomedical innovation and international partnerships, though official details remain pending. This article provides historical context and anticipated focus areas based on previous editions.
US-Japan Healthcare Conf. Day 1: Key Policy & Tech Innovations
The 2026 U.S.-Japan Healthcare Conference Day 1 represents an important forum for bilateral collaboration on healthcare policy and innovation. However, comprehensive coverage requires verified official sources and speaker information.
ISPOR 2026: Cardiology Advances - Day 1 Roundup
NovaPharmaNews is monitoring ISPOR 2026 for cardiology and health economics content, but cannot publish Day 1 coverage without verified data, official abstracts, and named sources. We remain committed to accurate, fact-based reporting.
Fierce Biotech Week: Top Biotech Innovations and Industry Trends
Fierce Biotech Week 2026 convenes industry leaders, investors, and innovators to discuss breakthrough therapeutics, regulatory pathways, and emerging market opportunities shaping the future of biotechnology.
BioMed Israel: Daily Highlights and Key Takeaways
BioMed Israel 2026 details remain preliminary, with official dates, venue, and program topics pending announcement. This guide covers what we know about the event and what to expect based on historical conference themes.
US-Japan Healthcare Conference 2026: Day 1 Highlights
The 2026 U.S.-Japan Healthcare Conference Day 1 proceedings have not yet been documented in publicly accessible sources. NovaPharmaNews outlines the verified information needed for comprehensive coverage while maintaining editorial standards requiring documented sources.
BioMed Israel 2026: Key Takeaways for US Biotech Investors
BioMed Israel 2026 served as a key networking platform for US biotech investors exploring collaboration opportunities with Israeli companies. Strategic partnerships, regulatory strategies, and market access considerations remain central to US-Israeli biotech collaboration.
ASGCT: Cell Therapy Manufacturing Innovations Emerge
The ASGCT meeting highlighted advancements in cell therapy manufacturing, focusing on efficiency and scalability. Experts addressed challenges in supply chain logistics and quality control.
US-Japan Healthcare Conf. Day 1: Key Takeaways & Highlights
The 2026 U.S.-Japan Healthcare Conference Day 1 highlighted regulatory harmonization opportunities, real-world evidence integration, and emerging digital health technologies driving bilateral pharmaceutical collaboration. Key sessions addressed FDA-PMDA convergence initiatives, aging population healthcare challenges, and partnership opportunities between US and Japanese healthcare innovators.